-
Article
Open AccessBi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
The purpose of this study is to identify prognostic markers and treatment targets using a clinically certified sequencing panel in multiple myeloma. We performed targeted sequencing of 578 individuals with pla...
-
Article
Erratum: Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
Correction to: Blood Cancer Journal (2016) 6, e453; doi:10.1038/bcj.2016.64 The purpose of this corrigendum is to publish grant support omitted in the manuscript 16-BCJ-0175T entitled, ‘Dose-dense and less dos...
-
Article
Open AccessDose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
Multiple myeloma (MM) is a heterogeneous disease with high-risk patients progressing rapidly despite treatment. Various definitions of high-risk MM are used and we reported that gene expression profile (GEP)-d...
-
Article
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma
-
Article
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols
To determine whether primary plasma cell leukemia (PPCL) remains a high-risk multiple myeloma feature in the context of contemporary therapy and gene-expression profiling (GEP), we reviewed records of 1474 pat...
-
Article
VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced ...
